The CD163-expressing macrophages recognize and internalize TWEAK. Potential consequences in atherosclerosis

Atherosclerosis

Volumn 207, Issue 1, 2009, Pages 103-110

  Moreno, Juan A ^a   Muñoz García, Begoña ^a   Martín Ventura, Jose L ^a   Madrigal Matute, Julio ^a   Orbe, Josune ^b   Páramo, Jose A ^b   Ortega, Luis ^c   Egido, Jesús ^a   Blanco Colio, Luis M ^a  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^b UNIVERSITY OF NAVARRA   (Spain)

^c HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

Carotid artery; CD163; Plasma; TWEAK

Indexed keywords

CD163 ANTIGEN; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR LIKE WEAK INDUCER OF APOPTOSIS; UNCLASSIFIED DRUG;

ADULT; AGED; ARTERIAL WALL THICKNESS; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAROTID ARTERY; CAROTID ENDARTERECTOMY; CLINICAL ARTICLE; CONTROLLED STUDY; ECHOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MACROPHAGE; MALE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN INTERACTION; REAL TIME POLYMERASE CHAIN REACTION; RNA EXTRACTION; WESTERN BLOTTING;

ADULT; AGED; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; BIOLOGICAL MARKERS; BIOLOGICAL TRANSPORT; CAROTID ARTERY DISEASES; CELL LINE; ENDARTERECTOMY, CAROTID; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MACROPHAGES; MALE; MIDDLE AGED; RECEPTORS, CELL SURFACE; RNA, MESSENGER; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TUMOR NECROSIS FACTORS;

EID: 70350444860     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2009.04.033     Document Type: Article

References (30)

1. Kristiansen M., Graversen J.H., Jacobsen C., et al. Identification of the haemoglobin scavenger receptor. Nature 409 (2001) 198-201
2. Møller H.J., Peterslund N.A., Graversen J.H., and Moestrup S.K. Identification of the hemoglobin scavenger receptor/CD163 as a natural soluble protein in plasma. Blood 99 (2002) 378-380
3. Droste A., Sorg C., and Högger P. Shedding of CD163, a novel regulatory mechanism for a member of the scavenger receptor cysteine-rich family. Biochem Biophys Res Commun 256 (1999) 110-113
4. Guetta J., Strauss M., Levy N.S., Fahoum L., and Levy A.P. Haptoglobin genotype modulates the balance of Th1/Th2 cytokines produced by macrophages exposed to free hemoglobin. Atherosclerosis 191 (2007) 48-53
5. Abraham N.G., and Drummond G. CD163 mediated hemoglobin-heme uptake activates macrophage HO-1, providing an anti-inflammatory function. Circ Res 99 (2006) 911-914
6. Bover L.C., Cardo-Vila M., Kuniyasu A., et al. A previously unrecognized protein-protein interaction between TWEAK and CD163: potential biological implications. J Immunol 178 (2007) 8183-8194
7. Chicheportiche Y., Bourdon P.R., Xu H., et al. TWEAK, a new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis. J Biol Chem 272 (1997) 32401-32410
8. Nakayama M., Harada N., Okumura K., and Yagita H. Characterization of murine TWEAK and its receptor (Fn14) by monoclonal antibodies. Biochem Biophys Res Commun 306 (2003) 819-825
9. Wiley S.R., and Winkles J.A. TWEAK, a member of the TNF superfamily, is a multifunctional cytokine that binds the TweakR/Fn14 receptor. Cytokine Growth Factor Rev 14 (2003) 241-249
10. Muñoz-García B., Martín-Ventura J.L., Martínez E., et al. Fn14 is upregulated in cytokine-stimulated vascular smooth muscle cells and is expressed in human carotid atherosclerotic plaques: modulation by atorvastatin. Stroke 37 (2006) 2044-2053
11. Blanco-Colio L.M., Martín-Ventura J.L., Munoz-Garcia B., et al. TWEAK and Fn14. New players in the pathogenesis of atherosclerosis. Front Biosci 12 (2007) 3648-3655
12. Blanco-Colio L.M., Martín-Ventura J.L., Muñóz-García B., et al. Identification of soluble tumor necrosis factor-like weak inducer of apoptosis (sTWEAK) as a possible biomarker of subclinical atherosclerosis. Arterioscler Thromb Vasc Biol 27 (2007) 916-922
13. Kralisch S., Ziegelmeier M., Bachmann A., et al. Serum levels of the atherosclerosis biomarker sTWEAK are decreased in type 2 diabetes and end-stage renal disease. Atherosclerosis 199 (2008) 440-444
14. Blanco-Colio L.M., Munoz-Garcia B., Martin-Ventura J.L., et al. 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors decrease Fas ligand expression and cytotoxicity in activated human T lymphocytes. Circulation 108 (2003) 1506-1513
15. Greenland P., Smith S.C., and Grundy S.M. Improving coronary heart disease assessment in asymptomatic people. Role of traditional risk factors and non-invasive cardiovascular tests. Circulation 104 (2001) 1863-1867
16. Beloqui O., Paramo J.A., Orbe J., et al. Monocyte cyclooxygenase-2 overactivity: a new marker of subclinical atherosclerosis in asymptomatic subjects with cardiovascular risk factors?. Eur Heart J 26 (2005) 153-158
17. Paramo J.A., Orbe J., Beloqui O., et al. Prothrombin fragment 1_2 is associated with carotid intima-media thickness in subjects free of clinical cardiovascular disease. Stroke 35 (2004) 1085-1089
18. Martin-Ventura J.L., Blanco-Colio L.M., Munoz-Garcia B., et al. NF-kappaB activation and Fas ligand overexpression in blood and plaques of patients with carotid atherosclerosis: potential implication in plaque instability. Stroke 35 (2004) 458-463
19. Martin-Ventura J.L., Blanco-Colio L.M., Gomez-Hernandez A., et al. Intensive treatment with atorvastatin reduces inflammation in mononuclear cells and human atherosclerotic lesions in one month. Stroke 36 (2005) 1796-1800
20. Levy A.P., Purushothaman R., Levy N.S., et al. Downregulation of the hemoglobin scavenger receptor in individuals with diabetes and Hp 2-2 genotype. Implications for the response to intraplaque hemorrahge and plaque vulnerability. Circ Res 101 (2007) 106-110
21. Fabriek B.O., Dijkstra C.D., and van den Berg T.K. The macrophage scavenger receptor CD163. Immunobiology 210 (2005) 153-160
22. Kristiansen M., Graversen J.H., Jacobsen C., et al. Identification of the hemoglobin scavenger receptor. Nature 409 (2001) 198-201
23. Graversen J.H., Madsen M., and Moestrup S.K. CD163: a signal receptor scavenging haptoglobin hemoglobin complexes from plasma. Int J Biochem Cell Biol 234 (2002) 309-314
24. Schaer C.A., Schoedon G., Imhof A., Kurrer M.O., and Schaer D.J. Constitutive endocytosis of CD163 mediates hemoglobin-heme and determines the noninflammatory and protective transcriptional response of macrophages to hemoglobin. Cir Res 99 (2006) 943-950
25. Polek T.C., Talpaz M., Darnay B.G., and Spivak-Kroizman T. TWEAK mediates signal transduction and differentiation of RAW264.7 cells in the absence of Fn14/TweakR. Evidence for a second TWEAK receptor. J Biol Chem 278 (2003) 32317-32323
26. Matsushita N., Kashiwagi M., Wait R., et al. Elevated levels of soluble CD163 in sera and fluids from rheumatoid arthritis patients and inhibition of the shedding of CD163 by TIMP-3. Clin Exp Immunol 130 (2002) 156-161
27. Møller H.J., de Fost M., Aerts H., Hollak C., and Moestrup S.K. Plasma level of the macrophage-derived soluble CD163 is increased and positively correlates with severity in Gaucher's disease. Eur J Haematol 72 (2004) 135-139
28. Schaer D.J., Schleiffenbaum B., and Bächli E.B. Soluble hemoglobin-haptoglobin scavenger receptor CD163 as a lineage specific marker in the reactive hemophagocytic syndrome. Eur J Haematol 74 (2005) 6-10
29. Walter R.B., Bächli E.B., Schaer D.J., Rüegg R., and Schoedon G. Expression of the hemoglobin scavenger receptor (CD163/HbSR) as immunophenotypic marker of monocytic lineage in acute myeloid leukemia. Blood 101 (2003) 3755-3756
30. Aristoteli L.P., Møller H.J., Bailey B., Moestrup S.Q., and Kritharides L. The monocytic lineage specific soluble CD163 is a plasma marker of coronary atherosclerosis. Atherosclerosis 184 (2006) 342-347